基于人/鼠嵌合模型的人黑色素瘤mage-3基因疫苗的免疫学作用  

Immune function of mage-3 gene vaccine in human melanoma based on human/mouse chimera model

作　　者：姜曼[1] 吴玉章[1] 倪兵[1] 

机构地区：[1]解放军第三军医大学全军免疫学研究所,重庆市400038

出　　处：《中国临床康复》2004年第2期396-398,F003,共4页Chinese Journal of Clinical Rehabilitation

基　　金：the Major State Basic Research Development Program of China(973 Program)No.2001CB510001

摘　　要：目的:利用人/鼠嵌合模型评价人黑色素瘤基因mage-3基因疫苗的免疫效果。方法:建立并鉴定Trimera动物模型,并用重组质粒mage-3/pCI-neo作为基因疫苗对其进行免疫。检测免疫动物脾细胞CTL的杀伤活性和血清中mage-3特异性抗体。结果:构建的Trimera模型脾脏和腹腔中出现了大量的人淋巴细胞。接种后,Trimera模型体内出现了效价为1:256的mage-3特异抗体。免疫动物CTL体外杀伤实验显示,注射基因疫苗的Trimera小鼠脾脏淋巴细胞对靶细胞LB373的最大杀伤率为50%左右,而对照小鼠只有10%以下的杀伤水平。结论:mage-3是一种理想的肿瘤疫苗,在人源化动物模型中能激发出特异的细胞和体液免疫,对共享mage-3抗原的各种肿瘤细胞的临床治疗提供了实验依据。AIM:To evaluate the immune effect of mage-3gene vaccine in human melanoma by human /mouse chimera mod el.METHODS:Trimera animal model was established a nd evaluated.It was immunized by recombinant plasmid ma ge-3/pCI-neo as vac cine.Killing ac-tivity of splenocyte cytotoxic T-Lymphocyte(CTL)and mage- 3anti-body-specific in blood serum of the i mmune animal was detected.RESULT S:Quantity of human lymphocyte was dis covered in the spleen and abdominal cavi ty of the established Trimera model.After vaccination,m age-3antibody-speci fic with the potency of 1:256was presented in Trimera mod-el.CTL killing experiments in vitro of the immune animal reveal that the maximum killing rate t o target cell L B373of Spleen lymphocyte of the Trimera mice was about 50% after vaccination comparing with that of below10%in control mice group.Mage-3is an ideal tumour vaccine.It can stimulate specific cell and bo dy fluid immunisation in h umanized animal model.Therefore,i t provides an exp erimental gist for clinical therapies in all kinds of tumo ur cells,which shar e same mage-3antig en.

关 键 词：人黑色素瘤 基因疫苗 免疫学 淋巴细胞 

分 类 号：R739.5[医药卫生—肿瘤] R-332[医药卫生—临床医学]